{"id":432544,"date":"2021-02-10T06:03:08","date_gmt":"2021-02-10T11:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=432544"},"modified":"2021-02-10T06:03:08","modified_gmt":"2021-02-10T11:03:08","slug":"can-b-corp-and-dr-karl-zarse-launch-immunex2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/","title":{"rendered":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2"},"content":{"rendered":"
\n

Targeting Medical Professionals and Direct-to-Consumer Sales Channels to Proactively Optimize Immune Systems<\/p>\n

HICKSVILLE,\u00a0NY, Feb. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire<\/u><\/a> — Can B Corp. (OTCQB:<\/a>\u00a0CANB<\/a>)\u00a0(\u201cCan B\u201d or the \u201cCompany\u201d), a\u00a0diversified health and wellness company, is pleased to announce that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM\/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2.<\/p>\n

According to Dr. Zarse,\u00a0ImmuneX2<\/a>\u00a0ingredients are correlated with optimizing your immune system before you need it. \u00a0The certified organic twice a day AM\/PM supplement is developed by a physician and prepackaged for convenient dosing.<\/p>\n

Can B and Dr. Zarse are now accepting orders for ImmuneX2, available at:<\/p>\n

\n https:\/\/www.immunex2.com\/immune<\/a>\u00a0and\u00a0https:\/\/www.CanbMD.com<\/a><\/p>\n

Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website.<\/p>\n

Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse\u2019s ImmuneX2 label.<\/p>\n

Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2.<\/p>\n

Dr. Karl Zarse stated, \u201cIt\u2019s been a pleasure working with such a professional team at Can B Corp. and its Pure Health subsidiary. This collaboration has made my dream come true in having an immune boosting system widely available to the public. I think it\u2019s going to be a game changer as to why keeping an optimized immune system is so important in order to live a healthy lifestyle. I look forward to working closely with Can B\u2019s existing sales channels and ever-expanding network to get ImmuneX2 widely distributed and used.\u201d<\/p>\n

According to Dr. Zarse, ImmuneX2\u2019s physician developed immunity optimization formula has both innate and adaptive immune functionality specifically targeted with ImmuneX2\u2019s proprietary customer blend focused on immune system optimization. \u00a0Dr. Zarse further states that \u201cNo other product that he is aware of, exceeds the dosages of this blend while avoiding issues of toxicity. \u00a0ImmuneX2 can compensate for variations in the client base including malabsorption issues, size differences and baseline health status. Maximum benefit is obtained not only by staying adherent to the daily supplement line, but also by following and learning an online education program.\u201d<\/p>\n

Dr. Karl Zarse is the founding member of\u00a0Idaho Spine and Pain. He is certified by the American Board of Interventional Pain Physicians and travels throughout the country to bring his patients the most advanced therapies available. For additional information on Dr. Karl Zarse, please visit:\u00a0http:\/\/www.idahospineandpain.com<\/a>.<\/p>\n

\n
\n The statements made herein have not been evaluated by the FDA. ImmuneX2 is not intended to diagnose, treat, cure, or prevent any disease<\/em>
\n <\/strong>.<\/p>\n

\n
\n About\u00a0Can B Corp.<\/u>
\n <\/strong>\n <\/p>\n

Can B Corp. (OTCQB:<\/a>\u00a0CANB<\/a>) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B is also a license holder of the LifeGuard\u00ae Brand in developing a line of consumer products. The Company has launched Super Foods, a line of nutritional supplements. Can B Corp. owns and operates an R&D and production facility in Lacey, WA and Green Grow Farms, a licensed hemp grow and cultivation in New York. To learn more about Can B Corp. and our comprehensive line of high quality CBD products, please visit:\u00a0Canbiola.com<\/a>\u00a0and\u00a0www.CanBCorp.com<\/a>, follow Can B Corp on Instagram<\/u><\/a>\u00a0and Facebook<\/u><\/a>, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.<\/p>\n

For more information about Can B Corp., please visit:\u00a0CanBCorp.com<\/a><\/p>\n

\n Twitter @CanBCorp<\/a>\n <\/p>\n

\n Instagram @canbcorp<\/a>\n <\/p>\n

\n Facebook @ Can B Corp<\/a>\n <\/p>\n

\n YouTube<\/a>\n <\/p>\n

\n
\n Forward-Looking Statements<\/u>
\n <\/strong>\n <\/p>\n

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.<\/p>\n

Investors and Media:<\/p>\n

IR@canbiola.com<\/p>\n

(917) 658-7878<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Targeting Medical Professionals and Direct-to-Consumer Sales Channels to Proactively Optimize Immune Systems HICKSVILLE,\u00a0NY, Feb. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB:\u00a0CANB)\u00a0(\u201cCan B\u201d or the \u201cCompany\u201d), a\u00a0diversified health and wellness company, is pleased to announce that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM\/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse,\u00a0ImmuneX2\u00a0ingredients are correlated with optimizing your immune system before you need it. \u00a0The certified organic twice a day AM\/PM supplement is developed by a physician and prepackaged for convenient dosing. Can B and Dr. Zarse are now accepting orders for ImmuneX2, … <\/p>\n

Continue reading “Can B Corp and Dr. Karl Zarse Launch ImmuneX2”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-432544","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCan B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Targeting Medical Professionals and Direct-to-Consumer Sales Channels to Proactively Optimize Immune Systems HICKSVILLE,\u00a0NY, Feb. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB:\u00a0CANB)\u00a0(\u201cCan B\u201d or the \u201cCompany\u201d), a\u00a0diversified health and wellness company, is pleased to announce that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM\/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse,\u00a0ImmuneX2\u00a0ingredients are correlated with optimizing your immune system before you need it. \u00a0The certified organic twice a day AM\/PM supplement is developed by a physician and prepackaged for convenient dosing. Can B and Dr. Zarse are now accepting orders for ImmuneX2, … Continue reading "Can B Corp and Dr. Karl Zarse Launch ImmuneX2"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T11:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Can B Corp and Dr. Karl Zarse Launch ImmuneX2\",\"datePublished\":\"2021-02-10T11:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/\"},\"wordCount\":830,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/\",\"name\":\"Can B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==\",\"datePublished\":\"2021-02-10T11:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-b-corp-and-dr-karl-zarse-launch-immunex2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Can B Corp and Dr. Karl Zarse Launch ImmuneX2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/","og_locale":"en_US","og_type":"article","og_title":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk","og_description":"Targeting Medical Professionals and Direct-to-Consumer Sales Channels to Proactively Optimize Immune Systems HICKSVILLE,\u00a0NY, Feb. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB:\u00a0CANB)\u00a0(\u201cCan B\u201d or the \u201cCompany\u201d), a\u00a0diversified health and wellness company, is pleased to announce that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM\/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse,\u00a0ImmuneX2\u00a0ingredients are correlated with optimizing your immune system before you need it. \u00a0The certified organic twice a day AM\/PM supplement is developed by a physician and prepackaged for convenient dosing. Can B and Dr. Zarse are now accepting orders for ImmuneX2, … Continue reading \"Can B Corp and Dr. Karl Zarse Launch ImmuneX2\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-10T11:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2","datePublished":"2021-02-10T11:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/"},"wordCount":830,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/","name":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==","datePublished":"2021-02-10T11:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDIyNyMzOTY4OTEyIzUwMDA0NTUzMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-b-corp-and-dr-karl-zarse-launch-immunex2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Can B Corp and Dr. Karl Zarse Launch ImmuneX2"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=432544"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=432544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=432544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=432544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}